Single-molecule, single-cell profiling of chromatin protein-protein interactions

Active Grant Awarded

Award ID
DP2CA325383
Recipient
Awarding agency
Obligated
$912,000

Award facts

Assistance listing
93.310 Trans-NIH Research Support
Completion date 4% complete
Funding agency
Office of the Director National Institutes of Health, Department of Health and Human Services
Place of performance
Wyoming, MI 49503, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, Office of the Director, awarded Van Andel Research Institute (doing business as VAI) $912,000 on September 10, 2026, under Assistance Listing 93.310, Trans-NIH Research Support. The grant, DP2CA325383, has $912,000 obligated and an ultimate completion date of August 31, 2031. Place of performance is Wyoming, Michigan 49503.

The project, "Single-Molecule, Single-Cell Profiling of Chromatin Protein-Protein Interactions," expands an existing epigenomics toolkit by integrating transcription factor profiling with chromatin context and adding a single-molecule readout for DNA methylation at protein-bound sites. The recipient's lab is engineering Tn5 transposase variants for transcription factor mapping and simultaneously profiling multiple chromatin proteins in single cells. Prior joint profiling of H3K4me3 and H3K27me3 organized healthy immune cells along a trajectory from activation to exhaustion.

The work will characterize the epigenetic events underlying a balanced immune response. It tests how Polycomb-mediated repression and DNA methylation shape immune activation in myelodysplastic syndromes and autoimmune disease, and whether the programs that prevent autoimmunity also restrict anti-tumor responses. The source describes no sub-recipients for this award.

Description

Abstract
The immune system must balance the need to eliminate threats while avoiding damage to healthy tissues. Clinical trials in myelodysplastic syndromes (MDS) revealed that polycomb proteins and DNA methylation establish epigenetic barriers that maintain this balance by limiting immune activation. Inhibition of these barriers can enhance anti-tumor immunity but may also trigger autoimmunity in certain contexts. Our overall goal is to build an epigenomics toolkit to identify gene-regulatory elements that distinguish "good" immune activation from "bad" immune activation. Specifically, I will define how epigenetic repression is altered in MDS and autoimmune disease, and whether the same programs that prevent autoimmunity also restrict anti-tumor responses. Existing methods cannot simultaneously measure polycomb-mediated repression, DNA methylation, and the DNA-binding transcription factors that control the immune response, and this has limited our ability to resolve the mechanistic interactions of these epigenetic programs in primary human tissues. To address this, my lab is developing a novel strategy for simultaneous single-cell profiling of multiple chromatin proteins, while engineering TN5 transposase variants for robust transcription factor mapping. Using joint profiling of histone modifications associated with transcriptional activation (H3K4ME3) and polycomb-mediated repression (H3K27ME3), we have found that our approach can organize healthy immune cells along the trajectory from activation to exhaustion. We now propose to expand this toolkit by integrating transcription factor profiling with chromatin context and adding a single-molecule readout for DNA methylation at protein-bound sites. This will enable US, for the first time, to systematically characterize the series of epigenetic events underlying a balanced immune response. To test how epigenetic barriers shape immune activity, we will first examine whether ASXL1 mutations and hypomethylating agents prolong transcription factor binding at normal immune gene targets or enable binding at novel, normally silenced loci. We will then contrast these MDS-associated changes with autoimmune immune activation to determine whether beneficial, cancer-fighting responses can be distinguished from harmful, self-reactive ones at the molecular level. We expect these insights will inform more selective therapeutic strategies for cancer and autoimmunity. In addition, the epigenomics toolkit developed through this work will broadly enable mechanistic studies of gene regulation in complex human tissues in health and disease.

Quick answers

Who received award DP2CA325383?

DP2CA325383 was awarded to Van Andel Research Institute by National Cancer Institute (National Institutes of Health) on September 10, 2026.

How much is award DP2CA325383 worth?

$912,000 has been obligated on DP2CA325383.

Which agency awarded DP2CA325383?

National Cancer Institute (National Institutes of Health) awarded DP2CA325383, with funding from Office of the Director (National Institutes of Health).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award